Ping Yan
5 Papers
Ping Yan is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Shukui Qin,Qiu Li,Shanzhi Gu,Xiaoming Chen,Lizhu Lin,Zishu Wang,Aibing Xu,Xi Chen,Cuncai Zhou,Zhenggang Ren,Lin Yang,Li Xu,Yuxian Bai,Lei Chen,Jun Li,Hongming Pan,Bangwei Cao,Weijia Fang,Wei Wu,Ge Wang,Ying Cheng,Zhuang Yu,Xu Zhu,Da Jiang,Yinying Lu,Huaming Wang,Jianming Xu,Li Bai,Yunpeng Liu,Hailan Lin,Changping Wu,Yang Zhang,Ping Yan,Chunlei Jin,Jianjun Zou +34 more
TL;DR: The AHELP trial as discussed by the authors evaluated the efficacy and safety of apatinib in patients with pretreated advanced hepatocellular carcinoma, and showed that the drug significantly improved overall survival compared with placebo, with a manageable safety profile.
195
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Zhenggang Ren,Shukui Qin,Zhiqiang Meng,Zhendong Chen,Xiaoli Chai,Jianping Xiong,Yuxian Bai,Lin Yang,Hong Zhu,Weijia Fang,Xiaoyan Lin,Xiaoming Chen,Enxiao Li,Linna Wang,Ping Yan,Jianjun Zou +15 more
TL;DR: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptable safety profile as mentioned in this paper.
Abstract P5-18-10: Mecapegfilgrastim for primary prophylaxis of neutropenia in 355 HER2+ breast cancer patients treated with neoadjuvant docetaxel in combination with trastuzumab and/or pyrotinib: Exploratory analysis from randomized, double-blind, phase 3 PHEDRA study
Min He,Benlong Yang,Jiong Wu,Zhenzhen Liu,Hongjian Yang,Jinhai Tang,Kun Wang,Yunjiang Liu,Haibo Wang,Peifen Fu,Shuqun Zhang,Qiang Liu,Zefei Jiang,Shusen Wang,Jian Huang,Chuan Wang,Shui Wang,Yongsheng Wang,Linlin Zhen,Xiaoyu Zhu,Shulin Liu,Ping Yan,Jianjun Zou +22 more
TL;DR: The effectiveness of mecapegfilgrastim, a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), as primary prophylaxis for neoadjuvant chemotherapy-induced neutropenia in BC patients was evaluated and trends were observed for grade 3/4 WBC count decreased in Cycle 1 to 4.
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
Qiu Li,Shukui Qin,Shanzhi Gu,Xiaoming Chen,Lizhu Lin,Zishu Wang,Aibing Xu,Xi Chen,Cuncai Zhou,Zhenggang Ren,Lin Yang,Li Xu,Yuxian Bai,Lei Chen,Jun Li,Hongming Pan,Bangwei Cao,Weijia Fang,Ping Yan,Chunlei Jin +19 more
TL;DR: Chinese patients account for more than 50% of hepatocellular carcinoma cases in the world and have special features in etiology, biological behavior, treatment strategy, and so on.
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Feng Wang,Shukui Qin,Xinchen Sun,Zhenggang Ren,Zhiqiang Meng,Zhendong Chen,Xiaoli Chai,Jianping Xiong,Yuxian Bai,Lin Yang,Hong Zhu,Weijia Fang,Xiaoyan Lin,Xiaoming Chen,Enxiao Li,Linna Wang,Ping Yan,Jianjun Zou +17 more
TL;DR: RCCEP occurrence positively associated with outcomes of camrelizumab in advanced HCC and the development of RCCEP was significantly associated with prolonged PFS and OS after adjusting for baseline covariates.